Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Verichem reference materials for microprotein testing

November 2021—Verichem Laboratories offers ready-to-use, liquid-stable clinical reference materials for microprotein testing, suitable for use with turbidimetric and colorimetric test methods. The products are intended for the calibration and calibration verification of clinical systems testing for total protein and albumin in urine and cerebral spinal fluid. The kit contains a five-level set with 15 mL of material at each level and provides 10 individual certified concentrations in an azide-free format, incorporating human protein components for optimum reactivity.

TaqMan panel updated to include mu strain

November 2021—Thermo Fisher Scientific has updated its research use only Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to include the mu strain. Laboratories can build their own panel from a menu of more than 50 verified real-time PCR assays that allows the user to identify relevant SARS-CoV-2 mutations and adapt as additional mutations and variants emerge.

Simplexa COVID-19, flu A/B assay gets CE mark

November 2021—DiaSorin Molecular announced that it has CE marked its Simplexa COVID-19 and Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B from a patient sample in one reaction well. The assay is designed for use on the Liaison MDX and is run directly from nasopharyngeal swabs without the need for off-board extraction.

Microbiologics SARS-CoV-2 virus antigen controls

November 2021—Microbiologics has launched its SARS-CoV-2 Whole Virus Antigen Control, which can be used in the point-of-care setting for the detection of SARS-CoV-2 antigens and for monitoring the extraction, amplification, and detection in nucleic acid testing. In antigen-based applications, the high titer formula provides a clear positive reaction to monitor the detection of SARS-CoV-2 viral antigens. Each kit contains six individually packaged lyophilized swabs.

Roche launches three respiratory panels in CE markets

November 2021—Roche launched in the CE market three molecular PCR diagnostic test panels to simultaneously detect and differentiate flu A, flu B, and respiratory syncytial virus; adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and parainfluenza 1, 2, 3, and 4. The tests can be run together or individually from a single nasopharyngeal swab specimen and run on the Cobas Omni Utility Channel for use with the Cobas 6800/8800 systems.

Bio-Rad launches CFX Opus Dx RT-PCR detection systems

November 2021—Bio-Rad launched its CFX Opus 96 Dx and CFX Opus 384 Dx systems, real-time PCR detection systems that have been listed with the FDA for IVD testing and that meet the CE-IVD requirement for IVD use in Europe. Both instruments are also registered with regulatory bodies for IVD use in Singapore and Canada.

Thermo Fisher appointed U.S. distributor of APAS Independence

November 2021—Clever Culture Systems signed a five-year agreement for Remel, a part of Thermo Fisher, to be the exclusive U.S. distributor of the APAS Independence. The FDA-cleared automated culture plate reader will be added to Thermo Fisher’s portfolio of microbiology products in the United States. Under the agreement, Thermo Fisher will provide sales and marketing, installation, maintenance, and support services to customers in the United States.

Hardy Diagnostics releases group A strep agar

November 2021—Hardy Diagnostics released its HardyChrom Group A Strep agar, a chromogenic medium recommended for the selective cultivation and differentiation of group A streptococcus from clinical specimens. Identification can be made based on colony color—the medium will display red-brown or red-orange colonies on the Hardy­Chrom Group A Strep agar when Streptococcus pyogenes is present; non-group A streptococcus isolates will appear as blue, clear, or white colonies.

MARKETPLACE

TRENDING